Anonymous: "A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination With Rituximab or DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-cell Non Hodgkin's Lymphoma", , 19 February 2013 (2013-02-19), pages 1-9, XP055128138, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCT0 1691898/2013_02_19 [retrieved on 2014-07-10] (B1)

D. DORNAN ET AL: "Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma", BLOOD, vol. 114, no. 13, 24 September 2009 (2009-09-24), pages 2721-2729, XP055075268, ISSN: 0006-4971, DOI: 10.1182/blood-2009-02-205500 (B1)

WO-A1-2009/012268 (B1)

LU D ET AL: "PHARMACOKINETICS (PK) OF ANTI-CD22 AND ANTI-CD79B ANTIBODY DRUG CONJUGATES (ADCS) IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS: RESULTS FROM PHASE I DOSE-ESCALATION STUDIES", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 93, no. Suppl. 1, February 2013 (2013-02), pages S77-S78, XP002731413, ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-CLINICAL-PHARMACOLOGY -AND-THERAPEUTICS (ASCPT); INDIANAPOLIS, IN, USA; MARCH 05 -09, 2013 (B1)

PALANCA-WESSELS MARIA CORINNA ET AL: "A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", BLOOD, vol. 120, no. 21, November 2012 (2012-11), page 56, XP002731412, & 54TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ATLANTA, GA, USA; DECEMBER 08 -11, 2012 (B1)

JOHN R GASDASKA ET AL: "An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 50, no. 3, 10 January 2012 (2012-01-10), pages 134-141, XP028461489, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2012.01.001 [retrieved on 2012-01-18] (B1)